Allogeneic Stem Cell Transplantation for Patients with Relapsed Chemorefractory Aggressive Non-Hodgkin Lymphomas

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 5, 2009, Pages 547-553

  Hamadani, Mehdi ^a   Benson Jr , Don M ^a   Hofmeister, Craig C ^a   Elder, Patrick ^a   Blum, William ^a   Porcu, Pierluigi ^a   Garzon, Ramiro ^a   Blum, Kristie A ^a   Lin, Thomas S ^a   Marcucci, Guido ^a   Devine, Steven M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Aggressive non Hodgkin lymphoma; Allogeneic stem cell transplantation; Graft versus host disease; Refractory; Relapsed

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DONOR SELECTION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; LOG RANK TEST; MALE; MANTLE CELL LYMPHOMA; MORTALITY; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; SALVAGE THERAPY; SIBLING; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63749116090     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.01.010     Document Type: Article

References (28)

1. Philip T., Armitage J.O., Spitzer G., et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316 (1987) 1493-1498
2. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
3. Verdonck L.F., van Putten W.L., Hagenbeek A., et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332 (1995) 1045-1051
4. Chen A.I., McMillan A., Negrin R.S., Horning S.J., and Laport G.G. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 14 (2008) 741-747
5. Chen C.I., Crump M., Tsang R., Stewart A.K., and Keating A. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 113 (2001) 202-208
6. Hamadani M., Benson Jr. D.M., Lin T.S., Porcu P., Blum K.A., and Devine S.M. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol 81 (2008) 425-431
7. Milpied N., Gaillard F., Moreau P., et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 22 (1998) 645-650
8. Schouten H.C., Bierman P.J., Vaughan W.P., et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 74 (1989) 2579-2584
9. Corradini P., Dodero A., Farina L., et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 21 (2007) 2316-2323
10. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111 (2008) 5530-5536
11. Le Gouill S., Milpied N., Buzyn A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26 (2008) 2264-2271
12. Kim S.W., Tanimoto T.E., Hirabayashi N., et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 108 (2006) 382-389
13. Doocey R.T., Toze C.L., Connors J.M., et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131 (2005) 223-230
14. Dhedin N., Giraudier S., Gaulard P., et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br J Haematol 107 (1999) 154-161
15. Juckett M., Rowlings P., Hessner M., et al. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. Bone Marrow Transplant 21 (1998) 893-899
16. Hamadani M., Awan F.T., Elder P., et al. Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma 49 (2008) 1893-1898
17. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
18. Barista I., Romaguera J.E., and Cabanillas F. Mantle-cell lymphoma. Lancet Oncol 2 (2001) 141-148
19. Hiddemann W., Longo D.L., Coiffier B., et al. Lymphoma classification-the gap between biology and clinical management is closing. Blood 88 (1996) 4085-4089
20. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244
21. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
22. Cullen M.H., Lister T.A., Brearley R.I., Shand W.S., and Stansfeld A.G. Histological transformation of non-Hodgkin's lymphoma: a prospective study. Cancer 44 (1979) 645-651
23. Rezvani A.R., Storer B., Maris M., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 26 (2008) 211-217
24. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22 (2004) 2172-2176
25. Kusumi E., Kami M., Kanda Y., et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 36 (2005) 205-213
26. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104 (2004) 3865-3871
27. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (2002) 4310-4316
28. Rezvani A.R., Norasetthada L., Gooley T., et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 143 (2008) 395-403